Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

aTYR Pharma INC

NASDAQ: ATYR · Life Sciences · 7 alerts · CIK 1339970

Share price
$5.24Close, Nov 16
Market cap
$13.4M
Shares outstanding
2.55MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All aTYR Pharma INC filings on SEC EDGAR ↗

6:05 AM ET 10-Q
Financial Results

aTYR Pharma Q3 2026 Results: Net Loss of $18.3M, Loss Narrows

For the nine months ended September 30, 2026, aTyr Pharma reported a consolidated net loss of $39.4 million, an improvement from the $60.2 million loss in the prior year period. Total assets decreased to $59.8 million from $93.0 million at year-end 2025, primarily due to a reduction in available-for-sale investments used to fund operations.

Key figure
Net loss $18.3M
4:08 PM ET 8-K
Financial Results

aTYR Pharma Financial Results

aTyr Pharma reported third quarter 2026 financial results, ending the period with $50.3 million in cash and investments, providing a runway into late 2028. The company reached alignment with the FDA on a Phase 3 study protocol for efzofitimod in pulmonary sarcoidosis and is prioritizing strategic partnerships to advance the program.

“During the last quarter we reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of our lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis patients with restrictive lung disease, a major form of interstitial lung disease (ILD) with a high unmet medical need. We believe the efzofitimod program is well-positioned, considering the late-stage development status in an indication with a multi-billion-dollar global market opportunity, and have determined that at this time the best way for us to advance efzofitimod is to prioritize strategic partnerships.”

Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.